ArticleMolecular neurodegeneration2023
A Trem2
Open access · goldAbstract read
In one paragraph
Article in Molecular neurodegeneration, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 45 citations in OpenAlex.
- The TREM2 R47H variant is associated with liver-plasma-brain axis dyshomeostasis in the 5xFAD mouse model of Alzheimer's disease.Neurobiology of aging · 2026Article
- Disruptions in RNA Splicing: A Key Regulator of Cognitive Impairment in Perioperative Neurocognitive Disorders.Neuroscience bulletin · 2026Review
- Microglial CD31 suppresses Aβ clearance and promotes Alzheimer pathology in 5×FAD mice.Nature communications · 2026Article
- Abi3Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Cholecalciferol (vitamin D3) is an agonist of the Alzheimer's disease-associated immune receptor TREM2.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- The gain-of-function TREM2-T96K mutation increases risk for Alzheimer's disease by impairing microglial function.Neuron · 2026Article
- Interplay between CD33 and TREM2 in Alzheimer's Disease: Potential Mechanistic Insights into Microglial Function in Amyloid Pathology.ACS chemical neuroscience · 2026Review
- Behavioral deficits and exacerbated neural and hemodynamic odor responses during lifespan of a mouse model of late onset Alzheimer's disease expressing humanized APOEε4 and Trem2*R47H.Frontiers in aging neuroscience · 2026Article
- Microglial phagocytosis in Alzheimer disease.Nature reviews. Neurology · 2026Review
- The TREM2 paradox in fibrosis: a unified mechanism for opposite outcomes across organs.Frontiers in immunology · 2026Review
- Inhibition of histone lysine demethylase restores learning and memory in aged mice.bioRxiv : the preprint server for biology · 2025Article
- Trem2bioRxiv : the preprint server for biology · 2025Article
- Single-nucleus multi-omics identifies shared and distinct pathways in Pick's and Alzheimer's disease.Science advances · 2025Article
- Roles of TREM2 in Alzheimer's disease.Translational neurodegeneration · 2025Review
- Super-Resolved Spatial Transcriptomics Reveals Early Changes in RNA Localization in the 5xFAD Hippocampus.bioRxiv : the preprint server for biology · 2025Article
- Modeling common Alzheimer's disease with high and low polygenic risk in human iPSC: A large-scale research resource.Stem cell reports · 2025Article
- Human and Mouse Alzheimer's Seeds Differentially Affect Amyloid Deposition and Microglia-Dependent Plaque Response in Aged Mice.Aging cell · 2025Article
- Unveiling blood biomarkers for neuronal hyperplasticity: Insights from AD molecular subtyping, a comprehensive review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Sleep Deprivation and Alzheimer's Disease: A Review of the Bidirectional Interactions and Therapeutic Potential of Omega-3.Brain sciences · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 1 institution in 1 country.
Kristine M TranDepartment of Neurobiology and Behavior, University of California, Irvine, USA.
Shimako KawauchiInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, USA.
Enikö A KramárDepartment of Neurobiology and Behavior, University of California, Irvine, USA.
Narges RezaieDepartment of Developmental and Cell Biology, University of California, Irvine, USA.
Heidi Yahan LiangDepartment of Developmental and Cell Biology, University of California, Irvine, USA.
Jasmine S SakrDepartment of Pharmaceutical Sciences, University of California, Irvine, USA.
Angela Gomez-ArboledasDepartment of Molecular Biology & Biochemistry, University of California, Irvine, USA.
Miguel A ArreolaDepartment of Neurobiology and Behavior, University of California, Irvine, USA.
Celia da CunhaInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, USA.
Jimmy PhanInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, USA.
Shuling WangTransgenic Mouse Facility, Office of Research, ULAR, Irvine, USA.
Sherilyn CollinsTransgenic Mouse Facility, Office of Research, ULAR, Irvine, USA.
Amber WalkerTransgenic Mouse Facility, Office of Research, ULAR, Irvine, USA.
Kai-Xuan ShiTransgenic Mouse Facility, Office of Research, ULAR, Irvine, USA.
Jonathan NeumannTransgenic Mouse Facility, Office of Research, ULAR, Irvine, USA.
Ghassan FilimbanDepartment of Developmental and Cell Biology, University of California, Irvine, USA.
Zechuan ShiDepartment of Neurobiology and Behavior, University of California, Irvine, USA.
Giedre MilinkeviciuteInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, USA.
Dominic I JavonilloInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, USA.
Katelynn TranInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, USA.
Magdalena GantuzInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, USA.
Stefania FornerInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, USA.
Vivek SwarupDepartment of Neurobiology and Behavior, University of California, Irvine, USA.
Andrea J TennerDepartment of Neurobiology and Behavior, University of California, Irvine, USA.
Frank M LaFerlaDepartment of Neurobiology and Behavior, University of California, Irvine, USA.
Marcelo A WoodDepartment of Neurobiology and Behavior, University of California, Irvine, USA.
Ali MortazaviDepartment of Developmental and Cell Biology, University of California, Irvine, USA.
Grant R MacGregorTransgenic Mouse Facility, Office of Research, ULAR, Irvine, USA. gmacg@uci.edu.
Kim N GreenDepartment of Neurobiology and Behavior, University of California, Irvine, USA. kngreen@uci.edu.ORCID 0000-0002-6049-6744
University of California, Irvine · US
Funding
UC Irvine MODEL-ADU54AG054349 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Craig E Stark · 2017 to 2026
$71.9MUniv.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9MUncover Strategies Used By Biological SystemsP50GM076516 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI NIE, QING · 2007 to 2016
$25.1MOrigins, properties, and therapeutic potential of cells that repopulate the microglia-depleted adult brainR01NS083801 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI Kim Green · 2014 to 2026
$5.6MMicroglia are necessary for cortical plaque formation in Alzheimer's diseaseRF1AG056768 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI GREEN, KIM · 2018 to 2018
$2.7MThe lipid amidase NAAA as a therapeutic target for Alzheimer's diseaseRF1AG065329 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI GREEN, KIM, PIOMELLI, DANIELE · 2020 to 2020
$2.3MOligodendrocyte heterogeneity in Alzheimer' s diseaseRF1AG071683 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI SWARUP, VIVEK, ZHANG, JING · 2021 to 2024
$2.2MOligodendrocyte heterogeneity in Alzheimer' s diseaseR01AG071683 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI SWARUP, VIVEK · 2024 to 2025
$1.2MNCI NIH HHS P30 CA062203NIA NIH HHS R01 AG071683NIA NIH HHS RF1AG056768NIA NIH HHS RF1 AG065329NIA NIH HHS RF1AG065329NIA NIH HHS RF1 AG071683NIA NIH HHS U54 AG054349NIGMS NIH HHS P50 GM076516NINDS NIH HHS R01 NS083801NINDS NIH HHS R01NS083801
Abstract
backgroundThe TREM2 R47H variant is one of the strongest genetic risk factors for late-onset Alzheimer's Disease (AD). Unfortunately, many current Trem2
methodsTrem2
resultsTrem2
conclusionsThe Trem2
Indexed as
Alzheimer DiseaseDemyelinating DiseasesAnimalsBrainCuprizoneDisease Models, AnimalMembrane GlycoproteinsMiceMicrogliaMutationPlaque, AmyloidReceptors, ImmunologicRNA SplicingCuprizoneMembrane GlycoproteinsReceptors, ImmunologicTrem2 protein, mouseAlzheimer’s DiseaseInflammationLTPMicrogliaMODEL-ADTREM2 R47H
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.